应用流式细胞技术研究乳球蛋白-2在卵巢上皮癌组织中的表达与治疗反应和预后的相关性

背景与目的：为寻找新的特异性和敏感性更高的预后标志物，探讨卵巢上皮性癌组织中乳球蛋白-2（Mammaglobin-2，MGB-2）的表达与卵巢上皮性癌患者治疗反应和预后的关系。方法：采用流式细胞技术（flow—cytometry technology，FCM）检测85例原发性卵巢上皮癌组织中MGB-2的表达，分析其与卵巢上皮性癌临床病理因素、治疗反应、生存时间之间的相关性。结果：卵巢上皮性癌组织中MGB-2表达阳性率为78％。其中治疗后CA125下降不满意患者的阳性率（85％）显著高于下降满意者（62％，P=0．018）；复发患者（83％）高于未复发患者（67％），但两者比较，差异无显著性（P=0．097）。单因素分析显示，MGB-2表达阳性患者的中位数生存时间（25个月）明显短于阴性患者（〉39个月，P=0．021）。结论：MGB-2阳性表达与卵巢上皮性癌患者的治疗反应和预后不良相关。

Relationship of MGB-2 expression and chemotherapy response and prognosis in human ovarian carcinoma

Background and purpose:In order to look for the new biomarker with higher specificity and sensitivity, we investigated the relationship between expression of MGB-2 and chemotherapy response, and tried to find out whether MGB-2 may sever as a prognostic factor for the patients with ovarian carcinoma. Methods:The expression of MGB-2 was detected by flow-cytometry technology in ovarian carcinoma tissue. We analyzed the correlations among MGB-2 expression and clinical pathological factors, therapeutic effect and prognosis of the patients with ovarian carcinoma.Results:Positive detection of MGB-2 was 78%.(66/885). For the patients whose serum CA125 level did not drop to normal level after two courses of chemotherapy, the MGB-2 positive rate was significantly higher than in those whose serum CA125 level decreased markedly ( 85% vs. 62%, P=0.018). The positive rate was also higher in patients with recurrent disease than in those without recurrence (83% vs. 67%, P=0.097). In univariate survival analysis, the expression of MGB-2 was significantly associated with median survival time (P=0.021).Conclusions:MGB-2 expression is correlated with chemotherapy response and poor prognostic for the patients with ovarian carcinoma.